{
  "meta": {
    "title": "40_Sle_And_Aps",
    "url": "https://brainandscalpel.vercel.app/40-sle-and-aps-9dae0590.html",
    "scrapedAt": "2025-11-30T12:28:43.642Z"
  },
  "questions": [
    {
      "text": "What type of hypersensitivity reaction is seen in systemic lupus erythematosus?",
      "choices": [
        {
          "id": 1,
          "text": "Type I"
        },
        {
          "id": 2,
          "text": "Type II"
        },
        {
          "id": 3,
          "text": "Type III"
        },
        {
          "id": 4,
          "text": "Type IV"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Type III </strong>hypersensitivity reaction (<strong>immune complex</strong> deposition) is seen in <strong>systemic&nbsp;lupus erythematosus.</strong></p>\n<p>Systemic lupus erythematosus (SLE) is an autoimmune condition in which <strong>autoantibodies</strong> are directed against a part of the nucleus such as double-stranded DNA, histone, ribonuclear proteins, etc. The presence of these autoantibodies leads to the deposition of immune complexes&nbsp;and activation of the complement system.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0822",
      "difficulty": "easy"
    },
    {
      "text": "Patients with which of the following complement deficiencies are at an increased risk of developing systemic lupus erythematosus?",
      "choices": [
        {
          "id": 1,
          "text": "C1q"
        },
        {
          "id": 2,
          "text": "C5"
        },
        {
          "id": 3,
          "text": "C3"
        },
        {
          "id": 4,
          "text": "C1 inhibitor"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>C1q</strong> <strong>complement deficiency</strong> is a <strong>risk factor</strong> for the development of systemic lupus erythematosus <strong>(SLE).</strong> </p>\n<p>Risk factors for SLE are:</p>\n<ul>\n<li>Genetic\n<ul>\n<li>Genetic defects resulting in <strong>C1q</strong>, C2, C4 complement deficiencies</li>\n<li>Presence of <strong>HLA DR3</strong></li>\n<li>Mutation in the TREX1 gene</li>\n</ul>\n</li>\n<li>Environmental\n<ul>\n<li class=\"p1\">Epstein-Barr virus (EBV) infection</li>\n<li class=\"p1\">Oral contraceptive pills/ hormone replacement therapy</li>\n<li class=\"p1\">Smoking</li>\n<li class=\"p1\">Prolonged exposure to silica</li>\n</ul>\n</li>\n</ul><hr><h3>Related Pearl: Complement deficiency and associated diseases</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>Complement protein</td>\n<td>Effects of deficiency</td>\n</tr>\n<tr>\n<td>C1, C2, C4</td>\n<td>Immune- complex disease (SLE)</td>\n</tr>\n<tr>\n<td>C3, Factor I</td>\n<td>Susceptibility to capsulated bacteria</td>\n</tr>\n<tr>\n<td>C5-C9</td>\n<td>Susceptibility to Neisseria</td>\n</tr>\n<tr>\n<td>Factor D. properdin (factor P)</td>\n<td>Susceptibility to capsulated bacteria and Neisseria.</td>\n</tr>\n<tr>\n<td>\n<p>DAF (Decay accelerating factor)</p>\n<p>CD 59</p>\n</td>\n<td>Paroxysmal nocturnal hemoglobinuria</td>\n</tr>\n<tr>\n<td>C1-inhibitor</td>\n<td>Hereditary angioneurotic edema</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0824",
      "difficulty": "medium"
    },
    {
      "text": "Anti-nuclear antibodies are required for the diagnosis of which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Scleroderma"
        },
        {
          "id": 2,
          "text": "Systemic lupus erythematosus"
        },
        {
          "id": 3,
          "text": "Rheumatoid arthritis"
        },
        {
          "id": 4,
          "text": "Sjogren's syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Antinuclear antibodies (ANAs) </strong>are required for the diagnosis of <strong>systemic lupus erythematosus.&nbsp;</strong></p>\n<p>ANAs are autoantibodies that bind to the contents of the cell nucleus. They are present in &gt; 95% of patients with SLE. A positive antinuclear antibody ( ANA ) test with a titer of at least 1:80 is the obligatory entry criterion along with the additive criteria in 7 clinical and 3 immunologic domains. If a total of &gt;10 points achieved, it is indicative of SLE according to <strong>2019 EULAR/ACR Classification Criteria </strong>for Systemic Lupus Erythematosus (SLE)&nbsp;</p>\n<p>Most sensitive antibody for SLE: <strong>ANA</strong></p>\n<p>Most specific antibody for SLE: <strong>Anti smith</strong> &gt; Anti dsDNA&nbsp;<br />ANA may also be positive in the other options but it is not a criterion for diagnosis of these conditions.</p>\n<p>The following antibodies are specific for their respective autoimmune conditions.&nbsp;</p>\n<ul>\n<li><strong>Scleroderma </strong>(option A)<strong>: Anti-topoisomerase I(Scl-70) </strong>and <strong>anti-centromere</strong> antibodies highly specific for Systemic sclerosis.</li>\n<li><strong>Rheumatoid arthritis</strong> (option C): <strong>RF</strong> and <strong>anti-CCP </strong>antibodies&nbsp;</li>\n<li><strong>Sjogren syndrome</strong> (option D): <strong>Anti-Ro, Anti-La&nbsp;</strong></li>\n</ul><hr><h3>Related Pearl: Antibodies in Systemic lupus erythematosus (SLE)</h3><table>\n<tbody>\n<tr>\n<td><strong>Antibody</strong></td>\n<td><strong>Prevelance %</strong></td>\n<td><strong>Antigen Recognized</strong></td>\n<td><strong>Clinical utility</strong></td>\n</tr>\n<tr>\n<td>Antinuclear Antibody</td>\n<td>98</td>\n<td>Multiple nuclear</td>\n<td>Best screening test; repeated -ve test make SLE unlikely</td>\n</tr>\n<tr>\n<td>Anti dS-DNA</td>\n<td>70</td>\n<td>DNA(double stranded)</td>\n<td>High titres are SLE specific &amp; in some patients correlates  with disease activity, nephritis &amp; vasculitis</td>\n</tr>\n<tr>\n<td>Anti-Sm</td>\n<td>25</td>\n<td>Protein complexed to 6 species of nuclear U1 RNA</td>\n<td>Specific for SLE; no definite correlations; most patients also have anti RNP <br />More common in black &amp; asians than white</td>\n</tr>\n<tr>\n<td>Anti-RNP</td>\n<td>40</td>\n<td>Protein complexed to U1 RNA</td>\n<td>Not Specific for SLE; high titre associated with syndromes that have overlap features of several rheumatic syndromes including SLE;<br />More common in blacks and whites </td>\n</tr>\n<tr>\n<td>Anti-Ro( SS-A)</td>\n<td>30</td>\n<td>Protein complexed to hY RNA,<br />Primarily 60kDA and 52kDA</td>\n<td>Not Specific for SLE; associated with sicca syndrome, predisposes to subacute cutaneous lupus &amp; to neonatal lupus with congenital heart block; associated with decrease risk of nephritis</td>\n</tr>\n<tr>\n<td>Anti-La( SS-B)</td>\n<td>10</td>\n<td>47kDa protein complexed to hY RNA</td>\n<td>Usually associated with anti-RO, associated with decreased  risk for nephritis</td>\n</tr>\n<tr>\n<td>Antihistone</td>\n<td>70</td>\n<td>Histones associated with DNA<br />(In nucleosome &amp; chromatin)</td>\n<td>More frequent in drug induced lupus than in SLE</td>\n</tr>\n<tr>\n<td>Antiphospholipid</td>\n<td>50</td>\n<td>Phospholipid,β2 glycoprotein1(β2 G1) cofactor , prothrombin</td>\n<td>3 tests available-ELISAs for cardiolipin &amp; β2 G1,<br />Sensitive prothrombin time (DRVVT)<br />Predisposes to clotting, fetal loss, thrombocytopenia</td>\n</tr>\n<tr>\n<td>Antierythrocyte</td>\n<td>60</td>\n<td>Erythrocyte membrane </td>\n<td> Measured as direct Coombs test , a small proportion devlop overt hemolysis</td>\n</tr>\n<tr>\n<td>Antiplatelet</td>\n<td>30</td>\n<td>Surface &amp; altered cytoplasmic antigens on platelets</td>\n<td>Associated with thrombocytopenia, but sensitivity &amp; specificity are not good:<br />This is not a useful clinical test</td>\n</tr>\n<tr>\n<td>Antineuronal<br />(includes antiglutamate receptor)</td>\n<td>60</td>\n<td>Neuronal &amp; lymphocyte surface antigens</td>\n<td>In some series, a positive test in CSF correlates with active CNS lupus</td>\n</tr>\n<tr>\n<td>Antiribosomal P</td>\n<td>20</td>\n<td>Protein in ribosomes</td>\n<td>In some series, a positive test serum correlates with depression or psychosis due to CNS lupus</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7035",
      "difficulty": "easy"
    },
    {
      "text": "A 25-year-old marathon runner presents with complaints of joint pain and rashes over the face. She says the rashes appear on exposure to the sun. On physical examination, a butterfly rash is seen over her face sparing the nasolabial folds. Which of the following antibodies will you evaluate to screen this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Anti-dsDNA antibodies"
        },
        {
          "id": 2,
          "text": "Anti-Sm antibodies"
        },
        {
          "id": 3,
          "text": "Antinuclear antibodies"
        },
        {
          "id": 4,
          "text": "Anti-histone antibodies"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of systemic lupus erythematosus (<strong>SLE</strong>). The best <strong>screening test</strong> in this condition is to evaluate for the presence of <strong>antinuclear antibodies </strong>(ANAs).</p><hr><h3>Related Pearl: Antibodies in Systemic lupus erythematosus (SLE)</h3><table>\n<tbody>\n<tr>\n<td><strong>Antibody</strong></td>\n<td><strong>Prevelance %</strong></td>\n<td><strong>Antigen Recognized</strong></td>\n<td><strong>Clinical utility</strong></td>\n</tr>\n<tr>\n<td>Antinuclear Antibody</td>\n<td>98</td>\n<td>Multiple nuclear</td>\n<td>Best screening test; repeated -ve test make SLE unlikely</td>\n</tr>\n<tr>\n<td>Anti dS-DNA</td>\n<td>70</td>\n<td>DNA(double stranded)</td>\n<td>High titres are SLE specific &amp; in some patients correlates  with disease activity, nephritis &amp; vasculitis</td>\n</tr>\n<tr>\n<td>Anti-Sm</td>\n<td>25</td>\n<td>Protein complexed to 6 species of nuclear U1 RNA</td>\n<td>Specific for SLE; no definite correlations; most patients also have anti RNP <br />More common in black &amp; asians than white</td>\n</tr>\n<tr>\n<td>Anti-RNP</td>\n<td>40</td>\n<td>Protein complexed to U1 RNA</td>\n<td>Not Specific for SLE; high titre associated with syndromes that have overlap features of several rheumatic syndromes including SLE;<br />More common in blacks and whites </td>\n</tr>\n<tr>\n<td>Anti-Ro( SS-A)</td>\n<td>30</td>\n<td>Protein complexed to hY RNA,<br />Primarily 60kDA and 52kDA</td>\n<td>Not Specific for SLE; associated with sicca syndrome, predisposes to subacute cutaneous lupus &amp; to neonatal lupus with congenital heart block; associated with decrease risk of nephritis</td>\n</tr>\n<tr>\n<td>Anti-La( SS-B)</td>\n<td>10</td>\n<td>47kDa protein complexed to hY RNA</td>\n<td>Usually associated with anti-RO, associated with decreased  risk for nephritis</td>\n</tr>\n<tr>\n<td>Antihistone</td>\n<td>70</td>\n<td>Histones associated with DNA<br />(In nucleosome &amp; chromatin)</td>\n<td>More frequent in drug induced lupus than in SLE</td>\n</tr>\n<tr>\n<td>Antiphospholipid</td>\n<td>50</td>\n<td>Phospholipid,β2 glycoprotein1(β2 G1) cofactor , prothrombin</td>\n<td>3 tests available-ELISAs for cardiolipin &amp; β2 G1,<br />Sensitive prothrombin time (DRVVT)<br />Predisposes to clotting, fetal loss, thrombocytopenia</td>\n</tr>\n<tr>\n<td>Antierythrocyte</td>\n<td>60</td>\n<td>Erythrocyte membrane </td>\n<td> Measured as direct Coombs test , a small proportion devlop overt hemolysis</td>\n</tr>\n<tr>\n<td>Antiplatelet</td>\n<td>30</td>\n<td>Surface &amp; altered cytoplasmic antigens on platelets</td>\n<td>Associated with thrombocytopenia, but sensitivity &amp; specificity are not good:<br />This is not a useful clinical test</td>\n</tr>\n<tr>\n<td>Antineuronal<br />(includes antiglutamate receptor)</td>\n<td>60</td>\n<td>Neuronal &amp; lymphocyte surface antigens</td>\n<td>In some series, a positive test in CSF correlates with active CNS lupus</td>\n</tr>\n<tr>\n<td>Antiribosomal P</td>\n<td>20</td>\n<td>Protein in ribosomes</td>\n<td>In some series, a positive test serum correlates with depression or psychosis due to CNS lupus</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6497",
      "difficulty": "medium"
    },
    {
      "text": "A school teacher presented with painful oral ulcers, photosensitive rashes, and arthralgia. Presence of which of the following antibodies would be diagnostic of her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Anti Ro/SS-A antibodies"
        },
        {
          "id": 2,
          "text": "Anti-Sm antibodies"
        },
        {
          "id": 3,
          "text": "Antinuclear antibodies"
        },
        {
          "id": 4,
          "text": "Anti-dsDNA antibodies"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario of oral ulcers, photosensitive rash, and arthralgia is suggestive of systemic lupus erythematosus (<strong>SLE</strong>). <strong>Anti-Sm antibodies</strong>&nbsp;are <strong>most</strong> <strong>specific</strong> for SLE and hence their presence is diagnostic of this condition.</p><hr><h3>Related Pearl: Antibodies in Systemic lupus erythematosus (SLE)</h3><table>\n<tbody>\n<tr>\n<td><strong>Antibody</strong></td>\n<td><strong>Prevelance %</strong></td>\n<td><strong>Antigen Recognized</strong></td>\n<td><strong>Clinical utility</strong></td>\n</tr>\n<tr>\n<td>Antinuclear Antibody</td>\n<td>98</td>\n<td>Multiple nuclear</td>\n<td>Best screening test; repeated -ve test make SLE unlikely</td>\n</tr>\n<tr>\n<td>Anti dS-DNA</td>\n<td>70</td>\n<td>DNA(double stranded)</td>\n<td>High titres are SLE specific &amp; in some patients correlates  with disease activity, nephritis &amp; vasculitis</td>\n</tr>\n<tr>\n<td>Anti-Sm</td>\n<td>25</td>\n<td>Protein complexed to 6 species of nuclear U1 RNA</td>\n<td>Specific for SLE; no definite correlations; most patients also have anti RNP <br />More common in black &amp; asians than white</td>\n</tr>\n<tr>\n<td>Anti-RNP</td>\n<td>40</td>\n<td>Protein complexed to U1 RNA</td>\n<td>Not Specific for SLE; high titre associated with syndromes that have overlap features of several rheumatic syndromes including SLE;<br />More common in blacks and whites </td>\n</tr>\n<tr>\n<td>Anti-Ro( SS-A)</td>\n<td>30</td>\n<td>Protein complexed to hY RNA,<br />Primarily 60kDA and 52kDA</td>\n<td>Not Specific for SLE; associated with sicca syndrome, predisposes to subacute cutaneous lupus &amp; to neonatal lupus with congenital heart block; associated with decrease risk of nephritis</td>\n</tr>\n<tr>\n<td>Anti-La( SS-B)</td>\n<td>10</td>\n<td>47kDa protein complexed to hY RNA</td>\n<td>Usually associated with anti-RO, associated with decreased  risk for nephritis</td>\n</tr>\n<tr>\n<td>Antihistone</td>\n<td>70</td>\n<td>Histones associated with DNA<br />(In nucleosome &amp; chromatin)</td>\n<td>More frequent in drug induced lupus than in SLE</td>\n</tr>\n<tr>\n<td>Antiphospholipid</td>\n<td>50</td>\n<td>Phospholipid,β2 glycoprotein1(β2 G1) cofactor , prothrombin</td>\n<td>3 tests available-ELISAs for cardiolipin &amp; β2 G1,<br />Sensitive prothrombin time (DRVVT)<br />Predisposes to clotting, fetal loss, thrombocytopenia</td>\n</tr>\n<tr>\n<td>Antierythrocyte</td>\n<td>60</td>\n<td>Erythrocyte membrane </td>\n<td> Measured as direct Coombs test , a small proportion devlop overt hemolysis</td>\n</tr>\n<tr>\n<td>Antiplatelet</td>\n<td>30</td>\n<td>Surface &amp; altered cytoplasmic antigens on platelets</td>\n<td>Associated with thrombocytopenia, but sensitivity &amp; specificity are not good:<br />This is not a useful clinical test</td>\n</tr>\n<tr>\n<td>Antineuronal<br />(includes antiglutamate receptor)</td>\n<td>60</td>\n<td>Neuronal &amp; lymphocyte surface antigens</td>\n<td>In some series, a positive test in CSF correlates with active CNS lupus</td>\n</tr>\n<tr>\n<td>Antiribosomal P</td>\n<td>20</td>\n<td>Protein in ribosomes</td>\n<td>In some series, a positive test serum correlates with depression or psychosis due to CNS lupus</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6501",
      "difficulty": "medium"
    },
    {
      "text": "An SLE patient is found to have a butterfly rash. Which of the following is an incorrect statement regarding this finding?",
      "choices": [
        {
          "id": 1,
          "text": "Most common acute rash in SLE"
        },
        {
          "id": 2,
          "text": "Spares the nasolabial folds"
        },
        {
          "id": 3,
          "text": "Increased risk of squamous cell carcinoma"
        },
        {
          "id": 4,
          "text": "Associated with scaling"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Butterfly rash</strong>&nbsp;or malar rash in a patient with SLE is not associated with an increased risk of squamous cell carcinoma.</p>\n<p>It is the <strong>most common</strong> type of <strong>acute</strong> skin rash seen in SLE. It is a photosensitive, erythematous, and <strong>scaly</strong> rash that is prominent over the <strong>cheeks</strong> and the <strong>nose</strong>.&nbsp;It <strong>spares</strong> the <strong>nasolabial folds.</strong></p>\n<p>Common causes of <strong>malar rash</strong> are as follows:</p>\n<ul>\n<li>Erysipelas</li>\n<li>Cellulitis&nbsp;</li>\n<li>Systemic lupus erythematosus</li>\n<li>Rosacea</li>\n<li>Pellagra</li>\n<li>Dermatomyositis</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0857",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common pulmonary manifestation of SLE?",
      "choices": [
        {
          "id": 1,
          "text": "Shrinking lung syndrome"
        },
        {
          "id": 2,
          "text": "Pleuritis"
        },
        {
          "id": 3,
          "text": "Intra alveolar hemorrhage"
        },
        {
          "id": 4,
          "text": "Interstitial inflammation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The most common pulmonary manifestation of SLE is <strong>pleuritis</strong>, with or without pleural effusion.</p>\n<p>The most common manifestations of different systems involved in SLE are:</p>\n<ul>\n<li>Musculoskeletal- arthritis and arthralgia</li>\n<li>Skin- photosensitivity</li>\n<li>Kidneys- proteinuria</li>\n<li><strong>Neurologic- cognitive impairment</strong></li>\n<li><strong>Cardiac- pericarditis</strong></li>\n<li>Pulmonary- pleuritis</li>\n<li><strong>Hematologic- anemia</strong></li>\n</ul><hr><h3>Related Pearl: Antibodies in Systemic lupus erythematosus (SLE)</h3><table>\n<tbody>\n<tr>\n<td><strong>Antibody</strong></td>\n<td><strong>Prevelance %</strong></td>\n<td><strong>Antigen Recognized</strong></td>\n<td><strong>Clinical utility</strong></td>\n</tr>\n<tr>\n<td>Antinuclear Antibody</td>\n<td>98</td>\n<td>Multiple nuclear</td>\n<td>Best screening test; repeated -ve test make SLE unlikely</td>\n</tr>\n<tr>\n<td>Anti dS-DNA</td>\n<td>70</td>\n<td>DNA(double stranded)</td>\n<td>High titres are SLE specific &amp; in some patients correlates  with disease activity, nephritis &amp; vasculitis</td>\n</tr>\n<tr>\n<td>Anti-Sm</td>\n<td>25</td>\n<td>Protein complexed to 6 species of nuclear U1 RNA</td>\n<td>Specific for SLE; no definite correlations; most patients also have anti RNP <br />More common in black &amp; asians than white</td>\n</tr>\n<tr>\n<td>Anti-RNP</td>\n<td>40</td>\n<td>Protein complexed to U1 RNA</td>\n<td>Not Specific for SLE; high titre associated with syndromes that have overlap features of several rheumatic syndromes including SLE;<br />More common in blacks and whites </td>\n</tr>\n<tr>\n<td>Anti-Ro( SS-A)</td>\n<td>30</td>\n<td>Protein complexed to hY RNA,<br />Primarily 60kDA and 52kDA</td>\n<td>Not Specific for SLE; associated with sicca syndrome, predisposes to subacute cutaneous lupus &amp; to neonatal lupus with congenital heart block; associated with decrease risk of nephritis</td>\n</tr>\n<tr>\n<td>Anti-La( SS-B)</td>\n<td>10</td>\n<td>47kDa protein complexed to hY RNA</td>\n<td>Usually associated with anti-RO, associated with decreased  risk for nephritis</td>\n</tr>\n<tr>\n<td>Antihistone</td>\n<td>70</td>\n<td>Histones associated with DNA<br />(In nucleosome &amp; chromatin)</td>\n<td>More frequent in drug induced lupus than in SLE</td>\n</tr>\n<tr>\n<td>Antiphospholipid</td>\n<td>50</td>\n<td>Phospholipid,β2 glycoprotein1(β2 G1) cofactor , prothrombin</td>\n<td>3 tests available-ELISAs for cardiolipin &amp; β2 G1,<br />Sensitive prothrombin time (DRVVT)<br />Predisposes to clotting, fetal loss, thrombocytopenia</td>\n</tr>\n<tr>\n<td>Antierythrocyte</td>\n<td>60</td>\n<td>Erythrocyte membrane </td>\n<td> Measured as direct Coombs test , a small proportion devlop overt hemolysis</td>\n</tr>\n<tr>\n<td>Antiplatelet</td>\n<td>30</td>\n<td>Surface &amp; altered cytoplasmic antigens on platelets</td>\n<td>Associated with thrombocytopenia, but sensitivity &amp; specificity are not good:<br />This is not a useful clinical test</td>\n</tr>\n<tr>\n<td>Antineuronal<br />(includes antiglutamate receptor)</td>\n<td>60</td>\n<td>Neuronal &amp; lymphocyte surface antigens</td>\n<td>In some series, a positive test in CSF correlates with active CNS lupus</td>\n</tr>\n<tr>\n<td>Antiribosomal P</td>\n<td>20</td>\n<td>Protein in ribosomes</td>\n<td>In some series, a positive test serum correlates with depression or psychosis due to CNS lupus</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7696",
      "difficulty": "easy"
    },
    {
      "text": "A 40-year-old man with history of SLE presented to your OPD with shortness of breath. It is associated with chest pain that worsens on inspiration. On auscultation, you notice a pleural friction rub. Investigations reveal the following. What is the most likely diagnosis?<div class='question-desc-html'><p>PFT - restrictive pattern, reduced lung volumes</p>\n<p>DLCO - reduced</p>\n<p>CT chest - elevated hemidiaphragm</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Lupus pneumonitis"
        },
        {
          "id": 2,
          "text": "Interstitial fibrosis"
        },
        {
          "id": 3,
          "text": "Shrinking lung syndrome"
        },
        {
          "id": 4,
          "text": "Intra-alveolar hemorrhage"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario along with elevated hemidiaphragm and no evidence of ILD on chest CT is suggestive of <strong>shrinking lung syndrome</strong> (SLS), which is a rare complication of systemic lupus erythematosus (<strong>SLE</strong>).</p>\n<p>It is characterized by <strong>dyspnea</strong> and episodes of <strong>pleuritic chest pain</strong>. These symptoms occur in the absence of pleural or parenchymal involvement.</p>\n<p><strong>PFT</strong> shows <strong>decreased lung volume</strong> with a <strong>restrictive</strong> pattern, and <strong>DLCO</strong> is often <strong>reduced</strong>. Radiological investigations show an <strong>elevated</strong> <strong>hemidiaphragm</strong> with no evidence of ILD.&nbsp;<br /><br />The following X-ray shows shrinking lung syndrome.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3d626efc66bc46af80f1c32000255b15x512x512.PNG\" alt=\"Explanation Image\"><p>Pulmonary manifestations seen in SLE are:</p>\n<ul>\n<li><strong>Pleuritis</strong> with or without pleural effusion-&nbsp;<strong>most common</strong> pulmonary manifestation.</li>\n<li><strong>Lupus pneumonitis</strong> - It is the inflammation of the lung tissue (pneumonitis) due to SLE (lupus).&nbsp;</li>\n<li>Interstitial lung fibrosis</li>\n<li>Shrinking lung syndrome</li>\n<li>Intra-alveolar hemorrhage</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6504",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common neurological manifestation seen in patients with systemic lupus erythematosus?",
      "choices": [
        {
          "id": 1,
          "text": "Seizures"
        },
        {
          "id": 2,
          "text": "Depression"
        },
        {
          "id": 3,
          "text": "Cognitive impairment"
        },
        {
          "id": 4,
          "text": "Polyneuropathy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>most common neurological</strong> manifestation seen in patients with systemic lupus erythematosus <strong>(SLE)</strong> is&nbsp;<strong>cognitive impairment.</strong></p>\n<p>It can manifest as&nbsp;<strong>impaired</strong>&nbsp;<strong>memory</strong>&nbsp;and reasoning. Other common&nbsp;neurological manifestations in SLE are psychosis, depression, and&nbsp;seizures.</p>\n<p>The most common manifestations of different systems involved in SLE are:</p>\n<ul>\n<li>Musculoskeletal- arthritis and arthralgia</li>\n<li>Skin- photosensitivity</li>\n<li>Kidneys- proteinuria</li>\n<li>Neurologic- cognitive impairment</li>\n<li>Cardiac- pericarditis</li>\n<li>Pulmonary- pleuritis</li>\n<li>Hematologic- anemia</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9946",
      "difficulty": "medium"
    },
    {
      "text": "A young girl is being evaluated for low mood, anhedonia, weight loss, and insomnia since past 1 month. On examination, multiple hesitation marks were seen on her left forearm. She was diagnosed with systemic lupus erythematosus (SLE) one year back. Which of the following autoantibodies is associated with this presentation?",
      "choices": [
        {
          "id": 1,
          "text": "Anti-ribosomal P antibodies"
        },
        {
          "id": 2,
          "text": "Anti-Ro/SSA antibodies"
        },
        {
          "id": 3,
          "text": "Anti-neuronal antibodies"
        },
        {
          "id": 4,
          "text": "Anti-histone antibodies"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario is suggestive of <strong>depression</strong> in a patient with <strong>SLE</strong>. It is associated with <strong>anti-ribosomal&nbsp;P</strong> antibodies.</p>\n<p>Antiribosomal P antibody is&nbsp;associated with <strong>psychosis</strong> or <strong>depression</strong> in SLE.</p><hr><h3>Related Pearl: Antibodies in Systemic lupus erythematosus (SLE)</h3><table>\n<tbody>\n<tr>\n<td><strong>Antibody</strong></td>\n<td><strong>Prevelance %</strong></td>\n<td><strong>Antigen Recognized</strong></td>\n<td><strong>Clinical utility</strong></td>\n</tr>\n<tr>\n<td>Antinuclear Antibody</td>\n<td>98</td>\n<td>Multiple nuclear</td>\n<td>Best screening test; repeated -ve test make SLE unlikely</td>\n</tr>\n<tr>\n<td>Anti dS-DNA</td>\n<td>70</td>\n<td>DNA(double stranded)</td>\n<td>High titres are SLE specific &amp; in some patients correlates  with disease activity, nephritis &amp; vasculitis</td>\n</tr>\n<tr>\n<td>Anti-Sm</td>\n<td>25</td>\n<td>Protein complexed to 6 species of nuclear U1 RNA</td>\n<td>Specific for SLE; no definite correlations; most patients also have anti RNP <br />More common in black &amp; asians than white</td>\n</tr>\n<tr>\n<td>Anti-RNP</td>\n<td>40</td>\n<td>Protein complexed to U1 RNA</td>\n<td>Not Specific for SLE; high titre associated with syndromes that have overlap features of several rheumatic syndromes including SLE;<br />More common in blacks and whites </td>\n</tr>\n<tr>\n<td>Anti-Ro( SS-A)</td>\n<td>30</td>\n<td>Protein complexed to hY RNA,<br />Primarily 60kDA and 52kDA</td>\n<td>Not Specific for SLE; associated with sicca syndrome, predisposes to subacute cutaneous lupus &amp; to neonatal lupus with congenital heart block; associated with decrease risk of nephritis</td>\n</tr>\n<tr>\n<td>Anti-La( SS-B)</td>\n<td>10</td>\n<td>47kDa protein complexed to hY RNA</td>\n<td>Usually associated with anti-RO, associated with decreased  risk for nephritis</td>\n</tr>\n<tr>\n<td>Antihistone</td>\n<td>70</td>\n<td>Histones associated with DNA<br />(In nucleosome &amp; chromatin)</td>\n<td>More frequent in drug induced lupus than in SLE</td>\n</tr>\n<tr>\n<td>Antiphospholipid</td>\n<td>50</td>\n<td>Phospholipid,β2 glycoprotein1(β2 G1) cofactor , prothrombin</td>\n<td>3 tests available-ELISAs for cardiolipin &amp; β2 G1,<br />Sensitive prothrombin time (DRVVT)<br />Predisposes to clotting, fetal loss, thrombocytopenia</td>\n</tr>\n<tr>\n<td>Antierythrocyte</td>\n<td>60</td>\n<td>Erythrocyte membrane </td>\n<td> Measured as direct Coombs test , a small proportion devlop overt hemolysis</td>\n</tr>\n<tr>\n<td>Antiplatelet</td>\n<td>30</td>\n<td>Surface &amp; altered cytoplasmic antigens on platelets</td>\n<td>Associated with thrombocytopenia, but sensitivity &amp; specificity are not good:<br />This is not a useful clinical test</td>\n</tr>\n<tr>\n<td>Antineuronal<br />(includes antiglutamate receptor)</td>\n<td>60</td>\n<td>Neuronal &amp; lymphocyte surface antigens</td>\n<td>In some series, a positive test in CSF correlates with active CNS lupus</td>\n</tr>\n<tr>\n<td>Antiribosomal P</td>\n<td>20</td>\n<td>Protein in ribosomes</td>\n<td>In some series, a positive test serum correlates with depression or psychosis due to CNS lupus</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6502",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common cardiac manifestation seen in patients with systemic lupus erythematosus?",
      "choices": [
        {
          "id": 1,
          "text": "Pericarditis"
        },
        {
          "id": 2,
          "text": "Myocarditis"
        },
        {
          "id": 3,
          "text": "Libman Sack endocarditis"
        },
        {
          "id": 4,
          "text": "Myocardial infarction"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Pericarditis</strong> is the most common cardiac manifestation seen in patients with&nbsp;<strong>systemic lupus erythematosus</strong>.</p>\n<p>Other cardiac manifestations include:</p>\n<ul>\n<li>Myocarditis</li>\n<li>Libman-Sacks endocarditis.</li>\n</ul>\n<p>Patients with SLE are at an increased<strong> risk </strong>for<strong> myocardial infarction,</strong> usually due to accelerated atherosclerosis.</p>\n<p>The most common manifestations of different systems involved in SLE are:</p>\n<ul>\n<li>Musculoskeletal- arthritis and arthralgia</li>\n<li>Skin- photosensitivity</li>\n<li>Kidneys- proteinuria</li>\n<li>Neurologic- cognitive impairment</li>\n<li>Cardiac- pericarditis</li>\n<li>Pulmonary- pleuritis</li>\n<li>Hematologic- anemia</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6505",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is a feature of arthritis in SLE?",
      "choices": [
        {
          "id": 1,
          "text": "Non-deforming arthritis"
        },
        {
          "id": 2,
          "text": "Predilection for large joints"
        },
        {
          "id": 3,
          "text": "Asymmetric involvement"
        },
        {
          "id": 4,
          "text": "Non-erosive arthritis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Non-erosive arthritis</strong> is a common feature of arthritis in SLE.</p>\n<p>Features of arthritis in SLE are:</p>\n<ul>\n<li><strong>Symmetrical</strong> and <strong>polyarticular</strong> arthritis </li>\n<li>A predilection for the <strong>small joints</strong> of the hand (the proximal interphalangeal and carpal joints)</li>\n<li><strong>Non-erosive</strong> and <strong>deforming arthritis</strong> <strong>(reducible)</strong></li>\n</ul>\n<p>In contrast to rheumatoid arthritis which is characterized by erosive, deforming joint involvement, SLE has non-erosive and deforming arthritis (reduciable).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0863",
      "difficulty": "easy"
    },
    {
      "text": "A young woman who is a known case of SLE develops proteinuria. The doctor suspects lupus nephritis and performs a renal biopsy. It shows the presence of wire loop appearance without glomerular proliferation. In which class of lupus nephritis will you categorize this patient's biopsy findings?",
      "choices": [
        {
          "id": 1,
          "text": "Mesangial proliferative lupus nephritis"
        },
        {
          "id": 2,
          "text": "Focal lupus nephritis"
        },
        {
          "id": 3,
          "text": "Diffuse lupus nephritis"
        },
        {
          "id": 4,
          "text": "Membranous lupus nephritis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Wire loop&nbsp;appearance</strong>&nbsp;without glomerular proliferation is seen in&nbsp;<strong>diffuse lupus nephritis (Class IV).</strong></p>\n<p>The capillaries are thickened due to the <strong>subendothelial deposits</strong> and appear as wire loops. It is the <strong>most</strong> <strong>common</strong> and <strong>most severe</strong> form of lupus nephritis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/61f60a4aeb574c178459f81e107d7445x1279x911.JPEG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>Renal involvement is common in patients with SLE. The majority of the patients will present with</p>\n<ul>\n<li>Proteinuria, nephrotic syndrome</li>\n<li>Microscopic hematuria, hypertension</li>\n<li>Urinary casts</li>\n<li>Abnormal renal function tests- elevated serum creatinine</li>\n<li>Low C3 and C4 levels</li>\n</ul>\n<p>&nbsp;</p><hr><h3>Related Pearl: Classification of Lupus Nephritis (International Society of Nephrology and Renal Pathology Society)</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Class&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>Findings</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Minimal mesangial lupus nephritis (class I)</p>\n</td>\n<td>\n<p><strong>Immune complex deposition</strong> in&nbsp;the mesangium without structural changes by light microscopy.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mesangial proliferative lupus nephritis (class II)</p>\n</td>\n<td>\n<p><strong>Mesangial cell proliferation</strong> with mesangial immune deposits</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Focal lupus nephritis (class III)</p>\n</td>\n<td>\n<p>Focal, segmental <strong>glomerulonephritis</strong> involving <strong>less than 50%</strong> of all glomeruli.</p>\n<p>Focal subendothelial deposits with or without mesangial changes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Diffuse lupus nephritis (class IV)</p>\n</td>\n<td>\n<p>The most common and severe form of lupus nephritis</p>\n<p>Diffuse&nbsp;<strong>glomerulonephritis</strong> involving <strong>more than 50%</strong> of all glomeruli</p>\n<p>Diffuse subendothelial deposits with or without mesangial changes<strong>. &ldquo;Wire loop&rdquo;</strong> structures on light microscopy.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Membranous lupus nephritis (class V)</p>\n</td>\n<td>\n<p>Global or segmental&nbsp;<strong>subepithelial</strong> immune deposits with or without mesangial proliferation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Advanced sclerosing lupus nephritis (class VI)</p>\n</td>\n<td>\n<p><strong>Sclerosis</strong> of <strong>more than 90%</strong> of the glomeruli&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li>Focal- Involves only a few glomeruli</li>\n<li>Diffuse- Involves almost all the glomeruli</li>\n<li>Segmental- Involves only a part of glomerulus</li>\n<li>Global- Involves entire glomerulus</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b83e16725c9e4acbae2e0ff8275ec1a5x1279x911.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6507",
      "difficulty": "medium"
    },
    {
      "text": "A 40 year old female presented to the OPD for her annual routine check-up. she is a patient of SLE diagnosed a decade ago, among the given options what is the most common cause of death in such patients?",
      "choices": [
        {
          "id": 1,
          "text": "Cardiovascular disease"
        },
        {
          "id": 2,
          "text": "Renal failure"
        },
        {
          "id": 3,
          "text": "Infections"
        },
        {
          "id": 4,
          "text": "Disseminated intravascular coagulation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>most common</strong> cause of <strong>death</strong> in patients with SLE after 10 years of disease is <strong>accelerated atherosclerosis</strong>.</p>\n<p>The leading causes of death in the first 10 years of the disease are infections and renal failure; subsequently, Cardiovascular events become increasingly frequent causes of mortality.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0866",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is recommended for all patients with SLE?",
      "choices": [
        {
          "id": 1,
          "text": "Hydroxychloroquine"
        },
        {
          "id": 2,
          "text": "NSAIDs"
        },
        {
          "id": 3,
          "text": "Methotrexate"
        },
        {
          "id": 4,
          "text": "Systemic steroids"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Hydroxychloroquine</strong> is recommended for all patients with SLE. It decreases the symptoms, reduces flares and organ damage.</p>\n<p>Important drugs used in the management of SLE are:</p>\n<ul>\n<li><strong>NSAIDs</strong>- used for a shorter period to reduce pain and fever. They are not used in all patients because of the increased risk of atherosclerosis and renal injury.</li>\n<li><strong>Hydroxychloroquine</strong> or chloroquine- should be used in all patients with SLE</li>\n<li><strong>Glucocorticoids</strong>\n<ul>\n<li><strong>topical</strong> glucocorticoids- in <strong>mild</strong> skin lesions</li>\n<li><strong>systemic</strong> steroids- in <strong>severe</strong> skin lesions and organ involvements.</li>\n</ul>\n</li>\n<li><strong>Immunosuppressive agents</strong>- used in combination with glucocorticoids in severe skin lesions and organ involvement. They help to reduce the dose and toxicity of glucocorticoids. Important agents are:\n<ul>\n<li>Methotrexate</li>\n<li>Azathioprine</li>\n<li>Mycophenolate mofetil and cyclophosphamide- immunosuppressive agents of choice in renal involvement.&nbsp;</li>\n</ul>\n</li>\n<li><strong>Biologic drugs</strong>- like belimumab and rituximab are used when there is no response to conventional drugs.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7517",
      "difficulty": "medium"
    },
    {
      "text": "A patient with a history of SLE presented with hematuria and proteinuria. Investigations revealed elevated creatinine and low C3, C4 levels. He was unresponsive to steroid therapy and his physician prescribed him belimumab for further management. What is the mechanism of action of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "TNF inhibitor"
        },
        {
          "id": 2,
          "text": "IL-1 antagonist"
        },
        {
          "id": 3,
          "text": "Anti CD-20 antibody"
        },
        {
          "id": 4,
          "text": "BAFF inhibitor"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario is suggestive of <strong>lupus nephritis.&nbsp;</strong><strong>Belimumab</strong> is a&nbsp;<strong>BAFF inhibitor</strong> used in patients with lupus nephritis who do not show response to initial therapy with steroids.</p>\n<p>Belimumab&nbsp;is a human monoclonal antibody that inhibits the soluble form of a B cell survival factor (known as <strong>BLyS</strong> or <strong>BAFF</strong>) which promotes the formation of memory B cells and autoantibodies. Belimumab inhibits this factor and therefore is used in the management of SLE.&nbsp;</p>\n<p>It is used in combination with either cyclophosphamide or MMF in patients with lupus nephritis who do not show response to initial therapy with steroids.</p>\n<p>CD20 is an antigen present on the B cells. <strong>Rituximab</strong> is an <strong>anti-CD20</strong> monoclonal antibody that is used in patients who are resistant to the standard therapies.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1120",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old man presented with fever, malaise, skin rashes, and arthralgia. On further evaluation, his serology was positive for ANA and anti-histone antibodies. Use of which of the following drugs could have led to this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Rifampin"
        },
        {
          "id": 2,
          "text": "Bupivacaine"
        },
        {
          "id": 3,
          "text": "Warfarin"
        },
        {
          "id": 4,
          "text": "Hydralazine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario with positive ANA and <strong>anti-histone antibodies</strong> point towards a diagnosis of <strong>drug-induced lupus erythematosus</strong>. <strong>Hydralazine</strong> which is a vasodilator&nbsp;is associated with the development of drug-induced lupus erythematosus.</p>\n<p>Drug-induced lupus erythematosus is an autoimmune condition caused due to exposure to certain medications. It completely <strong>resolves</strong> <strong>after</strong> the causative <strong>drug</strong> is <strong>discontinued</strong>. Important drugs associated with this condition are:</p>\n<ul>\n<li>Sulfonamides</li>\n<li>Hydralazine</li>\n<li>Isoniazid</li>\n<li>Infliximab</li>\n<li>Procainamide</li>\n<li>Propylthiouracil</li>\n<li>ACE inhibitors</li>\n<li>Thiazides</li>\n<li>TNF-alpha antagonists</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6508",
      "difficulty": "easy"
    },
    {
      "text": "What is the ratio of occurrence of drug-induced lupus erythematosus in females and males?",
      "choices": [
        {
          "id": 1,
          "text": "9:1"
        },
        {
          "id": 2,
          "text": "3:1"
        },
        {
          "id": 3,
          "text": "2:1"
        },
        {
          "id": 4,
          "text": "1:1"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The female to male ratio in&nbsp;drug-induced lupus erythematosus (<strong>DILE</strong>)&nbsp;is <strong>1:1. </strong></p>\n<p>The female&nbsp;to male ratio in systemic lupus erythematosus (<strong>SLE</strong>) is <strong>9:1</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Systemic lupus erythematosus (SLE)</strong></td>\n<td><strong>Drug-induced lupus erythematosus (DILE)</strong></td>\n</tr>\n<tr>\n<td>Age</td>\n<td>Common in young individuals&nbsp;</td>\n<td>Common in elderly (50-70 years)</td>\n</tr>\n<tr>\n<td>Female: male ratio</td>\n<td>9:1</td>\n<td><strong>1:1</strong></td>\n</tr>\n<tr>\n<td>Organs involved</td>\n<td>Can affect many organs</td>\n<td><strong>Skin</strong> is mainly involved. <strong>Renal</strong> and brain involvement are <strong>rare</strong></td>\n</tr>\n<tr>\n<td>Complement levels</td>\n<td>Reduced C3, C4 levels</td>\n<td>Normal C3, C4 levels</td>\n</tr>\n<tr>\n<td colspan=\"3\">Antibodies&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>-Antinuclear</td>\n<td>Common</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>-Antihistone</td>\n<td>Rare</td>\n<td><strong>Common</strong></td>\n</tr>\n<tr>\n<td>-Anti ds-DNA</td>\n<td>Common</td>\n<td><strong>Rare</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0821",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is true regarding drug-induced lupus erythematosus?",
      "choices": [
        {
          "id": 1,
          "text": "Renal involvement is rare"
        },
        {
          "id": 2,
          "text": "Commonly associated with anti ds-DNA"
        },
        {
          "id": 3,
          "text": "Common in females"
        },
        {
          "id": 4,
          "text": "Reduced C3 and C4 levels"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Renal involvement is rare in drug-induced lupus erythematosus.</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Systemic lupus erythematosus (SLE)</strong></td>\n<td><strong>Drug-induced lupus erythematosus (DILE)</strong></td>\n</tr>\n<tr>\n<td>Age</td>\n<td>Common in young individuals&nbsp;</td>\n<td>Common in elderly (50-70 years)</td>\n</tr>\n<tr>\n<td>Female: male ratio</td>\n<td>9:1</td>\n<td><strong>1:1</strong></td>\n</tr>\n<tr>\n<td>Organs involved</td>\n<td>Can affect many organs</td>\n<td><strong>Skin</strong> is mainly involved. <strong>Renal</strong> and brain involvement are <strong>rare</strong></td>\n</tr>\n<tr>\n<td>Complement levels</td>\n<td>Reduced C3, C4 levels</td>\n<td>Normal C3, C4 levels</td>\n</tr>\n<tr>\n<td colspan=\"3\">Antibodies&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>-Antinuclear</td>\n<td>Common</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>-Antihistone</td>\n<td>Rare</td>\n<td><strong>Common</strong></td>\n</tr>\n<tr>\n<td>-Anti ds-DNA</td>\n<td>Common</td>\n<td><strong>Rare</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0867",
      "difficulty": "medium"
    },
    {
      "text": "Antiphospholipid syndrome is associated with all of the following except:",
      "choices": [
        {
          "id": 1,
          "text": "Recurrent fetal loss"
        },
        {
          "id": 2,
          "text": "Thrombocytosis"
        },
        {
          "id": 3,
          "text": "Arterial thrombosis"
        },
        {
          "id": 4,
          "text": "Libman-Sacks endocarditis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Thrombocytosis is not associated with antiphospholipid syndrome (APS). On the contrary, <strong>thrombocytopenia</strong> is seen.</p>\n<p>APS is an autoantibody-mediated condition that is characterized by <strong>arterial </strong>thrombosis, <strong>venous</strong> <strong>thrombosis</strong>, and <strong>recurrent fetal loss</strong>. These autoantibodies bind to the phospholipids present on the endothelial cells and activate coagulation and thrombus formation.</p>\n<p>Important manifestations of <strong>venous thrombosis</strong> are:</p>\n<ul>\n<li>Deep vein thrombosis of legs</li>\n<li>Pulmonary embolism</li>\n<li>Livedo reticularis</li>\n<li>Cerebral venous thrombosis</li>\n</ul>\n<p>Important manifestations of <strong>arterial thrombosis</strong> are:</p>\n<ul>\n<li>Stroke, transient ischemic attacks</li>\n<li>Retinal artery thrombosis</li>\n<li>Myocardial ischemia</li>\n<li>Libman-Sacks endocarditis- due to the vegetations formed by platelet fibrin microthrombi</li>\n<li>Leg ulcers, gangrene of the digits</li>\n</ul>\n<p>Important <strong>obstetric </strong>manifestations are:</p>\n<ul>\n<li>Preeclampsia</li>\n<li>Recurrent fetal loss</li>\n<li>Premature birth</li>\n</ul>\n<p>Important <strong>hematological</strong> abnormalities are:</p>\n<ul>\n<li><strong>Thrombocytopenia</strong>- occurs due to increased platelet aggregation and thrombus formation&nbsp;</li>\n<li>Coombs positive <strong>hemolytic anemia</strong>- seen when autoantibodies attack red blood cells</li>\n<li>Thrombotic microangiopathic syndromes- thrombotic thrombocytopenic purpura (<strong>TTP</strong>) and hemolytic uremic syndrome (<strong>HUS</strong>)</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6503",
      "difficulty": "medium"
    },
    {
      "text": "A 34-year-old woman comes for evaluation of recurrent fetal losses. She has had 4 spontaneous abortions, all of them at <10 weeks of gestational age, and has a history of deep vein thrombosis. Which of the following antibodies is not useful in making a diagnosis in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Lupus anticoagulant"
        },
        {
          "id": 2,
          "text": "Anti-cardiolipin"
        },
        {
          "id": 3,
          "text": "Anti-beta-2 glycoprotein"
        },
        {
          "id": 4,
          "text": "Anti-beta-2 microglobulin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical history of &gt;3 spontaneous abortions at &lt;10 weeks of gestational age along with a history of deep vein thrombosis suggests a diagnosis of <strong>antiphospholipid syndrome (APS). </strong>Anti beta-2 microglobulin is not useful in diagnosing this condition.</p>\n<p>For the diagnosis of antiphospholipid syndrome, high titers of <strong>one or more</strong> of the following three antibodies should be demonstrated along with at least one clinical symptom of thrombosis or pregnancy complications:</p>\n<ul>\n<li><strong>Lupus anticoagulant (LA)</strong> -&nbsp;most<strong> specific</strong></li>\n<li><strong>Anticardiolipin (aCL) antibodies</strong> - most <strong>sensitive</strong></li>\n<li><strong>Anti-beta-2 glycoprotein</strong>&nbsp;antibodies</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6511",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old man presented with painful swelling of his right calf muscle. The clinical test shown below was positive. Investigations revealed elevated D-dimer, high titres of lupus anticoagulant and anti-cardiolipin antibodies. You would use all of the following drugs for his management except:",
      "choices": [
        {
          "id": 1,
          "text": "Warfarin"
        },
        {
          "id": 2,
          "text": "Glucocorticoids"
        },
        {
          "id": 3,
          "text": "Aspirin"
        },
        {
          "id": 4,
          "text": "Hydroxychloroquine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given findings of <strong>positive Moses'</strong>&nbsp;<strong>sign</strong> with elevated D-dimer, lupus anticoagulant, and anti-cardiolipin antibodies are suggestive of <strong>antiphospholipid</strong> <strong>syndrome</strong> (APS). Glucocorticoids are not useful in the general management of APS, they are used only in the treatment of catastrophic APS.</p>\n<p><strong>Squeezing</strong> of the relaxed calf muscles from <strong>side to side</strong> is painful as the thrombosed deep veins in the calf are always <strong>tender</strong>. This test is known as <strong>Moses&rsquo; sign</strong>.</p>\n<p>The clinical manifestations in APS occur due to the activation of coagulation and thrombus formation. Therefore, <strong>anticoagulants</strong> and <strong>antiplatelet</strong> agents are the mainstays in the <strong>treatment</strong>. Important drugs used are:</p>\n<ul>\n<li><strong>Warfarin</strong>- is an anticoagulant that inhibits vitamin K dependant epoxidase.</li>\n<li><strong>Low molecular weight heparins</strong> (LMWH)- warfarin cannot be used in pregnancy due to its teratogenicity. In these situations, LMWH is used for anticoagulation.</li>\n<li><strong>Aspirin</strong>- is an antiplatelet agent.</li>\n<li>Hydroxychloroquine- is an immunomodulatory agent that can be used to prevent recurrent thrombosis.</li>\n<li>Statins</li>\n</ul>\n<p><strong>Note</strong>: The only condition where <strong>corticosteroids</strong> are beneficial is <strong>catastrophic APS</strong>. It&nbsp;is a life-threatening rapidly progressive thromboembolic disease involving simultaneously <strong>three or more</strong> organs. It is seen in very few patients.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4bea1ea5a4424743b5a89390f5eabefa.GIF"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6512",
      "difficulty": "medium"
    }
  ]
}